PA5-18670

antibody from Invitrogen Antibodies

Targeting: ACOX2 BRCACOX, BRCOX, THCCox

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-18670

Provider

Invitrogen Antibodies

Product name

ACOX2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This antibody is predicted to react with rabbit based on sequence homology.

Reactivity

Human

Host

Goat

Isotype

IgG

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway.

Zhang Q, Zhang Y, Sun S, Wang K, Qian J, Cui Z, Tao T, Zhou J
Cell death & disease 2021 Jan 4;12(1):15

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

PA5-18670 (0.5 µg/mL) in Human Liver lysate with (B) and without (A) blocking with the immunising peptide, the primary antibody incubation was 1 hour and detected by chemiluminescence.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

PA5-18670 (0.5 µg/mL) in Human Liver lysate with (B) and without (A) blocking with the immunising peptide, the primary antibody incubation was 1 hour and detected by chemiluminescence.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 5 ACOX2 is downregulated in liver cancer. A The expression of ACOX2 gene in liver cancer tissues and paired paracancer tissues by using RT-qPCR. B The expression of ACOX2 protein in liver cancer tissues and normal control tissues was detected by using immunohistochemistry. The expression distribution of ACOX2 in normal liver tissue and HCC patient samples was evaluated in the THPA database. C The expression of ACOX2 mRNA in normal liver cells and liver cancer cells by using RT-qPCR (* P < 0.05 and ** P < 0.01). D The protein expression of ACOX2 in normal liver cells and liver cancer cells by Western blot (*** P < 0.001). E The mRNA expression of ACOX2 in the TCGA dataset (*** P < 0.001). F Survival analysis of the association between ACOX2 and overall survival time in HCC patients (based on the TCGA data, P = 0.0326).